Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Sacituzumab Tirumotecan (Sac-TMT) in Salivary Gland Cancers - Saint-Tropez (LACOG 1824) Trial

NCT07928193 is registered in ClinicalTrials.gov with Latin American Cooperative Oncology Group as lead sponsor.

NCT NCT07928193 Not yet recruiting Phase 2 64 participants (estimated) Started 2027 15 sites

Follow this trial by email Email me the PDF

Get the NCT07928193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started March 2027. Interventional study, Phase 2, 64 participants (estimated). Lead sponsor Latin American Cooperative Oncology Group; Brazil. Primary measures: Objective Response Rate (ORR) in Cohort 1 (ACC); Objective Response Rate (ORR) in Cohort 2 (Non-ACC).

How it compares

90 similar trials: same condition (Salivary Gland Neoplasms) and phase

Enrollment

This trial
64
Middle half
21 to 55
Median
35
Trials with a value
85

Months from start to completion

This trial
60
Middle half
38.6 to 90.3
Median
63.5
Trials with a value
78

Sites

This trial
15
Middle half
1 to 12
Median
4
Trials with a value
87
Posted results or a linked paper 50% 45 of 90 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Sacituzumab Tirumotecan (Sac-TMT) in Salivary Gland Cancers - Saint-Tropez (LACOG 1824) Trial
Lead sponsor
Latin American Cooperative Oncology Group
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 31, 2027
Completion date
March 31, 2032
Enrollment
64 (estimated)
Sites
15

Conditions

MeSH condition names; the registry's own terms follow.

Salivary Gland Neoplasms

Registry terms: adenoid cystic carcinoma of the salivary gland, salivary gland cancers

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
15
Countries
Brazil
Lead sponsor
Latin American Cooperative Oncology Group

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
Cohort 1: Adenoid Cystic Carcinoma (ACC) Experimental Sacituzumab Tirumotecan (Sac-TMT)
Show registry wording

Participants with advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC) of the salivary gland who have received no more than three prior non-curative systemic treatment regimens. Participants receive Sacituzumab Tirumotecan (Sac-TMT) monotherapy at 4 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle for up to 12 cycles, or until disease progression, unacceptable toxicity, or withdrawal of consent.

Cohort 2: Non-Adenoid Cystic Carcinoma (Non-ACC) Experimental Sacituzumab Tirumotecan (Sac-TMT)
Show registry wording

rticipants with advanced, recurrent, or metastatic non-adenoid cystic carcinoma (non-ACC) of the salivary gland who have received no more than three prior non-curative systemic treatment regimens. Participants receive Sacituzumab Tirumotecan (Sac-TMT) monotherapy at 4 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle for up to 12 cycles, or until disease progression, unacceptable toxicity, or withdrawal of consent.

Primary endpoints

Registered primary outcome measures; 2 primary.

Registered primary endpoints
Measure Time frame
Objective Response Rate (ORR) in Cohort 1 (ACC) Up to 12 cycles (approximately 12 months).
Show registry wording

Proportion of participants with a best overall response of complete response (CR) or partial response (PR) as determined by RECIST 1.1 in the Adenoid Cystic Carcinoma cohort.

Objective Response Rate (ORR) in Cohort 2 (Non-ACC) Up to 12 cycles (approximately 12 months).
Show registry wording

Proportion of participants with a best overall response of complete response (CR) or partial response (PR) as determined by RECIST 1.1 in the Non-Adenoid Cystic Carcinoma cohort.

Lead sponsor's other trials

Latin American Cooperative Oncology Group, most recent start first.

Similar trials

Same condition (Salivary Gland Neoplasms) and phase, most recent start first.